DBV Technologies(US:DBVT) Globenewswire·2025-07-29 20:17Core Insights - DBV Technologies has filed its 2025 Half-Year Report with the French market authority, AMF, for the period ending June 30, 2025 [1] - The company is focused on developing treatment options for food allergies and other immunologic conditions, utilizing its proprietary VIASKIN patch technology [2][3] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Châtillon, France, with operations in North America [3] - The company is dedicated to addressing significant unmet medical needs related to food allergies, particularly through epicutaneous immunotherapy (EPIT) [2] - The VIASKIN patch aims to desensitize individuals to allergens by introducing microgram amounts of biologically active compounds through intact skin [2] Clinical Focus - DBV Technologies is currently conducting clinical trials for its VIASKIN Peanut product, targeting peanut allergic toddlers aged 1 to 3 years and children aged 4 to 7 years [2]